IAG’s Team published a new article ‘Artificial intelligence-based Clinical Decision Support systems using advanced medical imaging & Radiomics’, Elsevier’s Current Problems in Diagnostic Radiology, June 2020
IAG, Image Analysis Group’s article ‘Artificial intelligence-based Clinical Decision Support systems using advanced medical imaging & Radiomics‘ just been published in the Elsevier’s journal ‘Current Problems in Diagnostic Radiology’, volume 49, issue 4, ahead of print online access here.
In today’s changing enviroment, Artificial Intelligence (AI) is poised to make a veritable impact in medicine.
Clinical decision support (CDS) is an important area where AI can augment the clinician’s capability to collect, understand and make inferences on an overwhelming volume of patient data to reach the optimal clinical decision.
Advancements in medical image analysis, such as Radiomics, and data computation, such as machine learning, have expanded our understanding of disease processes and their management.
In this article, we review the most relevant concepts of AI as applicable to advanced imaging-based clinical decision support systems,
- Introduction to AI-based methodologies
- Clinical decision support system
- Knowledge representation through ontologies
- Automated planning
- Intelligent agents
- Machine Learning approaches for CDSS
- Some of the most common ML techniques
- Medical imaging-centric AI-CDSS
- Advanced imaging & Radiomics for AI-CDSS
- Design and performance considerations for AI-CDSS
Find the full article: here or speak to our expert team: imaging.experts@localhost
is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development.